Riot

@lycanriot.bsky.social

29 // He/Him // ❤️ @chaibeanie.bsky.social //Banner by @spacelionexx.bsky.social // Icon by @artvm1s.bsky.social

GOOD NEWS! Phase I clinical trial results out of Johns Hopkins show a first-of-its-kind vaccine designed to target common KRAS mutations was safe AND stimulated KRAS-specific T-cell responses in 90% of study participants who were at HIGH risk of developing pancreatic ductal adenocarcinoma (PDAC).

Pancreatic Cancer Vaccine Triggers Immune Response Before Tumors Develop

Phase I results show early promise for a vaccine designed to prevent pancreatic cancer in people at high risk of developing the disease.

insideprecisionmedicine.com

“Pancreatic cancer mRNA vaccine shows lasting results in an early trial. Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.” This is why we should fund science. 🧪

Pancreatic cancer mRNA vaccine shows lasting results in an early trial

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.

nbcnews.com